Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio observacional para recopilar datos sobre cómo se usa aflibercept (Eylea) administrado mediante un dispositivo de dosificación pediátrico en bebés prematuros con retinopatía del prematuro en el Reino Unido (Reino Unido)

4 de noviembre de 2026 actualizado por: Bayer

Estudio de utilización de fármacos para Eylea 40 mg/mL utilizando el dispositivo de dosificación pediátrico PICLEO en bebés prematuros con retinopatía del prematuro en el Reino Unido

This is an observational study in which only data from babies with retinopathy of prematurity (ROP) who are being treated with aflibercept (Eylea) in prefilled syringe (PFS) using a paediatric dosing device (PDD) are collected and studied.

ROP is a condition that affects the eyes of preterm babies. It occurs when the baby's retina, the part of the eye that senses light, does not develop normally. This may result in vision problems, including blindness, if left untreated. Preterm babies are born before 37 weeks of pregnancy. ROP is more likely to develop in babies who are born before 32 weeks of pregnancy or weigh less than 1.5 kilograms at birth.

Aflibercept is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth of blood vessels in the retina.

Aflibercept in PFS given using a PDD is approved for the treatment of babies with ROP. The prefilled syringe will be fitted with an injection needle to give aflibercept. And a PDD is a tool used to give the right amount of aflibercept to children in a safe manner.

Since there are other treatments which are commonly used for babies with ROP, the extent of use of aflibercept given using a PDD is unknown.

The main purpose of this study is to:

  • find the number of preterm babies who are treated with aflibercept using a PDD in the UK
  • inform whether this number is enough to perform a study to learn about the long-term safety of aflibercept given using a PDD in babies with ROP

An additional purpose of this study is to describe characteristics including age, sex, and race, and signs and symptoms of ROP observed in babies being treated with aflibercept using a PDD.

The data will come from a database called the National Neonatal Research Database. The study will cover the period from March 2024 to March 2025, if the number of babies found is enough to perform the safety study. If not, data will be collected till April 2027.

In this study only available data from preterm babies born during the study period are collected. No visits or tests are required as part of this study.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Tipo de estudio

De observación

Inscripción (Estimado)

200

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Many Locations, Reino Unido
        • Reclutamiento
        • Many locations

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 1 año (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

All premature infants diagnosed with ROP and treated with Eylea PFS + PDD included in the National Neonatal Research Database (NNRD) during the study period in the UK.

Descripción

Inclusion Criteria:

  • Eligible infants within the NNRD include those who were:

    • 1. Born during the study period, i.e. from Q4/2023 following market introduction of Eylea PFS+PDD and 31st December 2026, and
    • 2. Received care in a neonatal unit that contributes data to the NNRD and the unit has agreed to participate in the study, and
    • 3. Diagnosed with ROP in any stage in at least one eye.

Exclusion Criteria:

  • Infants with missing data for gestational age at birth will be excluded.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: CROSS_SECTIONAL

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Premature infants diagnosed with ROP

Premature infants diagnosed with retinopathy of prematurity (ROP) and treated with aflibercept 0.4 mg using the Eylea 40 mg/mL prefilled syringe (PFS) in combination with the PICLEO paediatric dosing device (PDD) after marketing authorisation in UK and included in the National Neonatal Research Database (NNRD).

Eylea 40 mg/mL solution for injection in pre-filled syringe.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants treated with Eylea PFS+PDD upon completion of 1- or 3-years following market introduction
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years
  • To evaluate trends in drug utilization patterns of Eylea prefilled syringe (PFS)+Paediatric Dosing Device (PDD) in the ROP patient population. Exposure to Eylea is defined as a record of Eylea PFS+PDD in the National Neonatal Research Database (NNRD) database during admission to the neonatal unity during the study period.
  • To inform the decision on whether the number of preterm infants with ROP exposed to Eylea PFS+PDD is sufficient (n=200) for proceeding with a cohort study to collect data on long-term safety (ocular and systemic safety including neurodevelopmental outcome).
From market introduction of Eylea PFS+PDD in UK up to 3 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Summary of patient characteristics reported as number of participants with different categories
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Birth weight (in categories), sex, gestational age in weeks (in categories), ethnicity, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of maternal factors reported as number of participants with different categories
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Problems during pregnancy with mother, problems during pregnancy, mode of delivery, meconium stained liquor at delivery, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of comorbidities reported as number of participants with different categories
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Brain injury, necrotising enterocholitis, pulmonary hemorrhage, chronic lung disease, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of clinical condition and resource utilization reported as number of participants with different categories
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Respiratory support (mode of ventilation), cardiovascular (inotropic support), feeding (parenteral and enteral nutrition)

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of clinical condition and resource utilization reported as days
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Intensive care days, invasive ventilation days, parenteral nutrition days

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of outcomes of the premature infants reported as number of participants with different categories
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Survival to discharge from neonatal care (Y/N); Discharge, death, transferred to another hospital (in categories)

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of ocular disease and treatment reported as number of participants with different categories
Periodo de tiempo: From market introduction of Eylea PFS+PDD in UK up to 3 years

Number of Eylea injections in the neonatal unity, ROP surgery, ROP stage, ROP clock hours, ROP Max zone, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de marzo de 2024

Finalización primaria (Estimado)

31 de marzo de 2027

Finalización del estudio (Estimado)

30 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

26 de febrero de 2024

Primero enviado que cumplió con los criterios de control de calidad

11 de marzo de 2024

Publicado por primera vez (Actual)

18 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

4 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir